A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
Clinical trial NCT05773040 · RECRUITING
Trial details
- NCT number
- NCT05773040
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-14
- Primary completion
- 2028-12-31
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.